|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 139.40 USD | -3.09% |
|
-6.99% | -19.90% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 19Cr | 25Cr | 31Cr | 36Cr | 61Cr | |||||
Total Revenues | 19Cr | 25Cr | 31Cr | 36Cr | 61Cr | |||||
Cost of Goods Sold, Total | 4.42Cr | 5.51Cr | 6.56Cr | 8.57Cr | 12Cr | |||||
Gross Profit | 14Cr | 19Cr | 24Cr | 28Cr | 48Cr | |||||
Selling General & Admin Expenses, Total | 23Cr | 27Cr | 34Cr | 46Cr | 70Cr | |||||
R&D Expenses | 27Cr | 40Cr | 57Cr | 60Cr | 77Cr | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 50.52L | 50.53L | 50.52L | 50.52L | 60.01L | |||||
Other Operating Expenses, Total | 51Cr | 67Cr | 92Cr | 106.45Cr | 147.83Cr | |||||
Operating Income | -37Cr | -48Cr | -68Cr | -79Cr | -99Cr | |||||
Interest Expense, Total | -4.05Cr | -2.8Cr | -8.14Cr | -8.51Cr | -8.38Cr | |||||
Interest And Investment Income | 2L | 1.11Cr | 4.21Cr | 5.33Cr | 6.07Cr | |||||
Net Interest Expenses | -4.03Cr | -1.69Cr | -3.92Cr | -3.18Cr | -2.31Cr | |||||
Other Non Operating Income (Expenses) | -33.3L | -59.39L | 18.56L | 29T | -18.41L | |||||
EBT, Excl. Unusual Items | -41Cr | -50Cr | -72Cr | -82Cr | -101.98Cr | |||||
Merger & Related Restructuring Charges | -6L | - | - | - | - | |||||
Other Unusual Items | -2.5Cr | 2.08Cr | -2.87Cr | -9.17Cr | -25Cr | |||||
EBT, Incl. Unusual Items | -44Cr | -48Cr | -75Cr | -91Cr | -127.17Cr | |||||
Income Tax Expense | -17.58L | 13.83L | 25.55L | 37.07L | 50.26L | |||||
Earnings From Continuing Operations | -43Cr | -48Cr | -75Cr | -91Cr | -127.68Cr | |||||
Net Income to Company | -43Cr | -48Cr | -75Cr | -91Cr | -127.68Cr | |||||
Net Income - (IS) | -43Cr | -48Cr | -75Cr | -91Cr | -127.68Cr | |||||
Net Income to Common Incl Extra Items | -43Cr | -48Cr | -75Cr | -91Cr | -127.68Cr | |||||
Net Income to Common Excl. Extra Items | -43Cr | -48Cr | -75Cr | -91Cr | -127.68Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -3.88 | -3.91 | -5.34 | -5.57 | -6.42 | |||||
Basic EPS - Continuing Operations | -3.88 | -3.91 | -5.34 | -5.57 | -6.42 | |||||
Basic Weighted Average Shares Outstanding | 11Cr | 12Cr | 14Cr | 16Cr | 20Cr | |||||
Net EPS - Diluted | -3.88 | -3.91 | -5.34 | -5.57 | -6.42 | |||||
Diluted EPS - Continuing Operations | -3.88 | -3.91 | -5.34 | -5.57 | -6.42 | |||||
Diluted Weighted Average Shares Outstanding | 11Cr | 12Cr | 14Cr | 16Cr | 20Cr | |||||
Normalized Basic EPS | -2.29 | -2.54 | -3.2 | -3.12 | -3.2 | |||||
Normalized Diluted EPS | -2.29 | -2.54 | -3.2 | -3.12 | -3.2 | |||||
Supplemental Items | ||||||||||
EBITDA | -36Cr | -47Cr | -67Cr | -78Cr | -98Cr | |||||
EBITA | -37Cr | -48Cr | -68Cr | -79Cr | -99Cr | |||||
EBIT | -37Cr | -48Cr | -68Cr | -79Cr | -99Cr | |||||
EBITDAR | -34Cr | -45Cr | -65Cr | -74Cr | -94Cr | |||||
Effective Tax Rate - (Ratio) | 0.4 | -0.29 | -0.34 | -0.41 | -0.4 | |||||
Current Domestic Taxes | 1L | 3L | 4L | 4L | 6L | |||||
Current Foreign Taxes | 15.85L | 13.45L | 22.31L | 33.8L | 44.76L | |||||
Total Current Taxes | 16.89L | 16.14L | 26.09L | 37.36L | 50.53L | |||||
Deferred Domestic Taxes | -34.47L | -2L | -54T | -29T | -27T | |||||
Total Deferred Taxes | -34.47L | -2L | -54T | -29T | -27T | |||||
Normalized Net Income | -26Cr | -31Cr | -45Cr | -51Cr | -64Cr | |||||
Interest on Long-Term Debt | 4.05Cr | 2.64Cr | 8.17Cr | 8.49Cr | 8.38Cr | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | - | - | - | - | - | |||||
Research And Development Expense From Footnotes | 28Cr | 40Cr | 58Cr | 60Cr | 78Cr | |||||
Net Rental Expense, Total | 1.92Cr | 2.42Cr | 2.45Cr | 3.62Cr | 3.56Cr | |||||
Imputed Operating Lease Interest Expense | 1.22Cr | 55.82L | 1.19Cr | 1.85Cr | 2.32Cr | |||||
Imputed Operating Lease Depreciation | 69.64L | 1.86Cr | 1.26Cr | 1.77Cr | 1.24Cr | |||||
Stock-Based Comp., R&D Exp. (Total) | 1.78Cr | 2.64Cr | 3.59Cr | 4.77Cr | 7Cr | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., SG&A Exp. (Total) | 2.82Cr | 3.13Cr | 3.89Cr | 4.92Cr | 8.27Cr | |||||
Stock-Based Comp., Other (Total) | 13L | 13L | - | - | - | |||||
Total Stock-Based Compensation | 4.73Cr | 5.9Cr | 7.48Cr | 9.68Cr | 15Cr |
- Stock Market
- Equities
- INSM Stock
- Financials Insmed Incorporated
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















